← Leaderboards
Richard Scott Struthers
Neurocrine Biosciences, Inc.
$7,292,984
Attributed
$7,292,984
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2010–18$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$7,292,984 · 8
By mechanism
R44$6,234,242 · 3
R43$1,058,742 · 5
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Property”
- Mitchell J Malone · Texas A&M Research Foundation$344,583,004
- Gary D Acton · University Of California-Davis$320,373,312
- Everette D Joseph · Howard University$250,079,293
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Antonio J Busalacchi · University Of Maryland, College Park$243,972,016
- Eric J Barron · Pennsylvania State Univ University Park$243,972,016
Research focus
PropertyBaseAgonistReceptorPharmaceutical PreparationsEvaluationCyclic AmpSomatostatinToxicologyDrug CandidateInnovationPreparationPharmaceutical ChemistryPharmacologic SubstanceDrug DiscoverySignal TransductionPeptidesChronic PainG-Protein-Coupled ReceptorsGovernmentPainOralAdenomaPersons
Grant awards (12)
Biased Agonism In GPCR Drug Discovery: Application To Somatostatin Agonists$1,354,308
R44 · FY2018 · DK · contact PI
Biased Agonism In GPCR Drug Discovery: Application To Somatostatin Agonists$1,448,103
R44 · FY2017 · DK · contact PI
Discovery of novel small molecule drugs for Cushing's disease$299,510
R43 · FY2017 · DK · contact PI
Small molecule somatostatin agonists for neuropathic pain$326,121
R44 · FY2015 · NS · contact PI
Biased Agonism In GPCR Drug Discovery: Application To Somatostatin Agonists$1,162,633
R44 · FY2014 · DK · contact PI
Biased Agonism In GPCR Drug Discovery: Application To Somatostatin Agonists$999,917
R44 · FY2013 · DK · contact PI
Biased Agonism In GPCR Drug Discovery: Application To Somatostatin Agonists$282,070
R43 · FY2011 · DK · contact PI
Biosensors of GPCR Activation & Inhibition for Drug Discovery$237,895
R43 · FY2010 · GM · contact PI
Novel Non-Peptide Antagonists of the GnRH Receptor$471,580
R44 · FY2002 · HD
Novel non-peptide agonists of the melanocortin receptor$139,336
R43 · FY2002 · DK
Novel Non-Peptide Antagonists of the GnRH Receptor$471,580
R44 · FY2001 · HD
NOVEL NON-PEPTIDE ANTAGONIST OF THE GNRH RECEPTOR$99,931
R43 · FY2000 · HD